This review highlights immune checkpoints like TIGIT and GITR that enhance T cell responses in gastrointestinal oncology, suggesting new treatment possibilities.
Key Points
Immune checkpoints such as TIGIT and GITR are changing therapeutic strategies in gastrointestinal oncology.
Research shows that VISTA and STING pathways enhance the body's anti-tumor response, offering new avenues for treatment.
TIM-3 is associated with T cell fatigue and represents a potential target against immune evasion in tumors.
Combining immune checkpoint therapies with traditional treatments could improve patient outcomes in GI cancers.